Lynk Pharmaceuticals
Shanghai, China· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
A clinical-stage biotech developing targeted small molecule therapies for cancer and autoimmune disorders.
OncologyImmunology
Technology Platform
Integrated small molecule drug discovery platform utilizing structure-based design and translational medicine for oncology and immunology targets.
Opportunities
Potential for out-licensing advanced candidates to global pharma companies seeking innovative assets for the Chinese and Asian markets.
Risk Factors
Clinical failure of lead assets could significantly impact valuation, given the company's concentrated pipeline in competitive therapeutic areas.
Competitive Landscape
Operates in the highly competitive kinase inhibitor field but differentiates through novel chemical entities aimed at improved safety and efficacy profiles.